Chick Jonathan, Lehert Philippe, Landron Frederic
Department of Psychiatry, University of Edinburgh, Royal Edinburgh Hospital, Edinburgh, UK.
J Psychopharmacol. 2003 Dec;17(4):397-402. doi: 10.1177/0269881103174017.
The study aimed to discover whether acamprosate reduces the severity of relapse for those patients undergoing abstinence-orientated treatment who are unable to abstain completely. Data on patients' alcohol consumption from 15 placebo-controlled treatment studies (n = 3309) were examined to test whether, at a given time point, patients who have taken one or more drinks since the last assessment ('relapsers', n = 1010) take alcohol on fewer days, report lower average number of drinks per day, and consume less alcohol in total with acamprosate compared to placebo. These studies had varying duration (90 days, 180 days and 360 days). There were four dates that were common to some studies (days 30, 90, 180 and 360). Among relapsers, acamprosate was significantly associated with less quantity (Q) and frequency (F) of drinking compared to placebo in each of the four follow-up periods (p < 0.001). The differences were most marked for the product Q x F (overall weekly consumption). For each period, there were fewer who were drinking an average of five or more drinks per day in the acamprosate compared to the placebo groups. Acamprosate helps reduce the severity of relapse in patients undergoing abstinence-orientated treatment.
该研究旨在探究对于那些接受以戒酒为导向治疗但无法完全戒酒的患者，阿坎酸是否能降低复发的严重程度。对15项安慰剂对照治疗研究（n = 3309）中患者饮酒的数据进行了检查，以测试在给定时间点，自上次评估以来饮用了一杯或多杯酒的患者（“复发者”，n = 1010）与服用安慰剂相比，服用阿坎酸后饮酒天数是否减少、每日平均饮酒量是否更低以及饮酒总量是否更少。这些研究的持续时间各不相同（90天、180天和360天）。部分研究有四个共同的日期（第30天、90天、180天和360天）。在复发者中，在四个随访期的每一个中，与安慰剂相比，阿坎酸与饮酒量（Q）和饮酒频率（F）显著降低相关（p < 0.001）。对于乘积Q×F（每周总消费量），差异最为明显。在每个时间段，与安慰剂组相比，服用阿坎酸的患者中平均每天饮用五杯或更多酒的人数更少。阿坎酸有助于降低接受以戒酒为导向治疗的患者复发的严重程度。
